XiaoMi-AI文件搜索系统
World File Search Systemdecrease
CMIP6偏见的驱动器驱动器。第一部分：北半球
摘要：厄尔尼诺（ElNiño） - 南部振荡（ENSO）影响季节性大西洋热带气旋（TC）活性，通过对TC Genesis重要的环境条件进行影响。然而，未来气候变化对ENSO和大西洋TC之间的电信联系的影响尚不确定，因为预计气候变化会影响ENSO和平均气候状态。我们在热带通道域上使用了天气研究和预测模型，在不同的ENSO条件下，在历史和未来的气候下，在历史和未来的气候下模拟了5-MENT的大西洋TC季节。实验：每月变化的气候学，东部太平洋厄尔尼诺市，中部埃尔·埃尔尼诺尼诺和拉尼娜。与中央太平洋的埃尔尼诺（ElNiño）相比，在东部太平洋期间，历史模拟产生的大西洋TC较少，与观测和其他建模研究一致。对于每个ENSO状态，未来的模拟与大西洋TC产生了类似的远程连接，与历史模拟中一样。特别是，LaNiña继续增强大西洋TC活性，而Elniño继续抑制大西洋TC，与ElNiño中部相比，在东部太平洋地区，埃尔尼诺尼诺（ElNiño）在东部太平洋期间受到更大的抑制作用。我们的结果表明，ENSO将来将对季节性大西洋TC预测有用。In addition, we found a decrease in the Atlantic TC frequency in the future relative to historical regardless of ENSO state, which was associated with a future increase in northern tropical Atlantic vertical wind shear and a future decrease in the zonal tropical Paci fi c sea surface temperature (SST) gradient, correspond- ing to a more El Niño – like mean climate state.
临时报告1月1日至2024年9月30日
increased by 11% to EUR 81.8 million (EUR 73.8 million) • Elements Cloud ARR decrease from previous quarter was 1% • Net Revenue Retention for Elements Cloud was 104 % • Revenue for Elements Cloud increased by 9% to EUR 20.7 million (EUR 19.0 million) • ARR for Cloud Protection for Salesforce increased by 38% to EUR 10.2 million (EUR 7.4 million) • CPSF Revenue increased by 20% to EUR 2.4 million (EUR 2.0 million) •网络安全咨询收入下降了1％，至750万欧元（770万欧元）•针对特定的环境的EBITDA调整后的EBITDA为190万欧元（-230万欧元）•影响EBITDA可比性（IAC）的项目为-040万欧元（-020万欧元）。•与咨询有关的商誉在第三季度受到1550万欧元的损害
2025建筑展望东北调查结果
Increase Decrease No change Artificial intelligence 42% 1% 57% Document management software 40% 0% 60% Accounting software 38% 1% 61% Estimating software 36% 1% 63% Project management software 34% 5% 61% Client relationship management (CRM) software 27% 1% 72% Fleet tracking/management software 26% 4% 71% Tool/asset management/tracking 25% 4% 71% Building Information Modeling (BIM) 24% 0% 76％项目协作软件23％7％70％人力资源（HR）软件21％3％76％越野生产20％4％76％调度软件20％3％77％无人机19％5％76％76％76％的预先资格预先验证软件19％5％76％76％76％自主设备或工具1％1％1％1％1％1％1％1％1％1％1％的4％％4％4％52％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％4％52 13％3％85％3-D打印6％7％87％机器人6％8％86％
处方信息的亮点
警告：胚胎毒性1 1.1用法1.1肺动脉高压2剂量和给药2.1推荐剂量2.2剂量2.2孕妇在女性的妊娠试验3剂量和强度3剂量和优势的女性中，4.1偶然性4.1妊娠4.1妊娠4.2高度4.3浓度4.3浓度固定有机体4.4固定有机剂有机体（4.4） 5 WARNINGS AND PRECAUTIONS 5.1 Embryo-fetal Toxicity 5.2 Macitentan-Containing Products REMS 5.3 Hepatotoxicity 5.4 Hypotension 5.5 Hemoglobin Decrease 5.6 Worsening Pulmonary Veno-Occlusive Disease (PVOD) 5.7 Visual Loss 5.8 Hearing Impairment 5.9 Fluid Retention 5.10 Combination with Other PDE5 Inhibitors 5.11 Decreased Sperm Count 5.12 Prolonged勃起6不良反应6.1临床试验经验6.2后市场后经验
免费的AIOPS-FOUNDATION的问题
a- MTTA的增加，MTTR的增加并减少MTBF B-降低MTTA，MTTR的增加并减少MTBF C- MTTA的MTBF C-降低。MTTR的减少并减少MTBF D-降低MTTA。减少MTTR并增加MTBF
2024收益报告
Tokyo, February 13, 2025 2024 Earnings Report FY2024 Highlights (vs. FY2023) Revenue increased by 10.9% to JPY 3,149.8 billion Core revenue at constant FX increased by 8.4% to JPY 2,958.4 billion Adjusted operating profit at constant FX increased by 7.5% to JPY 782.7 billion On a reported basis, adjusted operating profit increased by 3.3% to JPY 751.9 billion Operating profit increased by 3.7% to JPY 697.2 billion Profit decreased by 3.9% to JPY 463.4 billion Free cash flow decreased by JPY 273.2 billion to JPY 170.5 billion The Company plans to pay an annual dividend per share of JPY 194 (a dividend payout ratio of 74.3%) FY2025 Forecasts (vs. FY2024) Revenue is forecast to increase by 3.9% to JPY 3,273.0 billion Core revenue at constant FX is forecast to increase by 6.6% to JPY 3,232.0 billion Adjusted operating profit at constant FX is forecast to increase by 8.4% to JPY 815.0 billion On a reported basis, adjusted operating profit is forecast to decrease by 2.2% to JPY 735.0 billion Operating profit is forecast to decrease by 3.8% to JPY 671.0 billion Profit is forecast to decrease by 2.9% to JPY 450.0 billion Free cash flow is forecast to increase by JPY 177.5 billion to JPY 348.0 billion The Company plans to offer an annual dividend per share of JPY 194 (a dividend payout ratio以76.5％的速度）请参阅第16页的“数据表”，以获取更多财务数据。JT集团总裁兼首席执行官Masamichi Terabatake的评论：“我很高兴地报告，尽管我们在运营环境中面临着挑战，但2024 JT集团的绩效在收入和调整后的运营利润方面达到了创纪录的收入和调整后的利润。我们的主要指标Constant FX处的调整后的营业利润增加了7.5％。在烟草业务中，JT集团的利润增长引擎，绩效是由可燃物中的稳固价格驱动的。此外，我们正在朝着2028年对RRP业务的野心稳步发展。我们的优先投资HTS的地理扩展在2024年底达到了24个市场。我们在每个市场中都有HTS细分市场的份额，在日本，最大的HTS市场，我们的份额在上一季度达到了12.6％。成功地收购了Vector Group Ltd。考虑到我们的股东退货政策，我们计划为2024财年支付每股194日元的年度股息。在2025年的业务计划中，覆盖2025年至2027年，我们的目标是通过通过定价和市场份额增长来增强收入，同时增强盈利能力，以继续提高可燃收入的投资回报率（ROI）。在RRP中，尽管对HTS类别的投资加强了投资，但我们希望在当前业务计划期间对收益有利。在接下来的三年期间，我们预计在恒定FX时调整后的营业利润将在高单位数字中的平均复合年增长率上升。我们打算在长期到长期内为我们的4S模型*利益相关者提供增量价值。我们计划按照我们的股东退货政策稳步增长股息，该政策的目标是75％。
基于细胞的基因疗法β-丘脑贫血
Targeting ineffective erythropoiesis [4] Activin receptor traps Sotatercept Ligand trap to inhibit Phase 2 trial with 16 TDT Effective and well tolerated Hypertension, muscle negative regulator of late- patients between 2012- 2014, Notable reductions in trans- spasm, headache stage erythropoiesis in administered as subcutaneous fusion requirements observed in most TGF β (improves贫血）注射每3周；在3周注射患者中被裁员一次作为副作用的FDA的副作用ASED输血负担，在治疗高度治疗中> 20％的治疗> 20％，≥33％的肺动脉高 - 但在2例患者中的7和≥50％的肺动脉估计是≥24wk luspater 2 31 the frient frientient fiper-niftient frientient 2 31 the the the the the the the the the the in 31 pain, tein that acts as a trap for patients, administered as Approved by FDA for treat- arthralgia, dizziness, activin receptor (decrease subcutaneous injection every ment of anemia failing to res- hypertension and oxidative stress and ane- 3 wk; decrease transfusion pond to erythropoiesis hyperuricemia mia in β - thalassemia burden noted in 26 （81％）MDS 3级或以上的刺激剂在任何2周上> 20％患者。 在第30周，超负荷。 迷宫炎，复发性1例患者，uti降低，腹胀，脾脏大小为第12周，体重增加表明未批准脾脏量增加。 小儿年龄组肝素的增加，但铁或铁蛋白没有变化。 另一项2期试验超越预终止。 和泛素化）2阶段研究尚未开始。患者。在第30周，超负荷。迷宫炎，复发性1例患者，uti降低，腹胀，脾脏大小为第12周，体重增加表明未批准脾脏量增加。小儿年龄组肝素的增加，但铁或铁蛋白没有变化。另一项2期试验超越预终止。和泛素化）2阶段研究尚未开始。adverse events like going believe study (phase thromboembolic events 3 trial) High cost of therapy JAK 2 inhibitors [4] Ruxolitinib Improved ineffective Phase 2a trial with 30 TDT Oral therapy High cost of therapy erythropoiesis, reversal patients, administered as oral Sustained reduction in (18,500 INR per 10 of splenomegaly by in- daily dose; a decrease in脾脏的大小改善了片剂的预片）JAK2级联脾脏大小从基线为输血血红蛋白-1.7每天的给药从基线到肝素需要的第12-19.7％，基线的增加到时间增加，这会减少铁质细胞增多率，昏迷，30-26.8％。调节铁代谢[4] Mini Hepcidins限制了铁的吸收，第2阶段试验，TDT缺乏已发表的较少性 - 发表的降低过载的超负荷患者，具有心肌文献，以皮下注射为皮下注射，每2 wk；由于患者的风险福利不良，因此被终止。铁蛋白减少铁吸收，第1阶段试验（口服）恶魔已发表的数据可用于缺乏已发表的抑制剂防止超负荷（仅触发临时临时临床前研究文献（VIT-2763）铁波素内在化的铁水平下降。tmprss6增加了第2阶段试验在TDT缺乏性的缺乏性抑制剂肝素抑制剂（通过抑制患者中，用作文献基因TMPRSSS6）的抑制性抑制剂的缺乏，从而在每4周中增加了每4个WK的下降/ d。
鲁本大学环境可持续性战略
• Remediation of specific issues causing inefficient energy use in college estate from the prioritised list • Energy use & carbon emissions for the college, per m2, per student etc., and rate of decrease over time • Refurbishment standard / building fabric standard for new acquisitions, and ongoing improvement of existing building stock • Dates from which to no longer use natural gas • Efficiency of lights, appliances, cooking equipment • Energy controls & feedback [Links with priority: Education and Research] • Education, feedback, incentives, involvement in management decisions of building users (staff and students) [Links with priority: Education and Research] • Thermal comfort standards – or more accurately, internal temperatures & other air quality issues (note the university's ‘functional estate' heating standard of 19C in winter 2022/23) • Purchasing of renewable electricity • Installation of solar PV / other on-site renewable options
理事会的参考委员会E报告...
501 Fragrance Regulation 502 Tribally-Directed Precision Medicine Research 503 Unregulated Hemp-Derived Intoxicating Cannabinoids, and Derived Psychoactive Cannabis Products (DPCPs) 504 FDA Regulation of Biosimilars 505 Mitigating the Harms of Colorism and Skin Bleaching Agents 506 Screening for Image Manipulation in Research Publications 507 Ban on Dual Ownership, Investment, Marketing or Distribution of Recreational Cannabis by Medical Cannabis Companies 508 AMA to support regulations to decrease overdoses in children due to ingestion of edible cannabis 509 Addressing Sarcopenia and its Impact on Quality of Life 510 Study to investigate the validity of claims made by the manufacturers of OTC Vitamins, Supplements and “Natural Cures” 511 National Penicillin Allergy Day and Penicillin Allergy Evaluation & Appropriate Delabeling 512 AED位于513 Biotin补充包装免责声明的阿片类药物过量逆转代理
未经审计财务报表
调整内容：所得税费用 - - - 折旧 1,971 16 - 利息收入 - - - 14,255 (8,181) (3,360) 可收回所得税增加/（减少） - - - 应收账款和预付款增加/（减少） (539,181) (999) - 应付资本分配增加/（减少） 0 - 62 存货增加/（减少） (196,013) - - 可收回所得税增加/（减少） (15,286) - - 应付关联方款项增加/（减少） 1,004,388 1,081,902 - 贷款一年内到期的增加/（减少） 9,286 - - 递延所得税增加/（减少） 3,169 - - 应付账款和应计费用增加/（减少） 170,807 (990) (835) 451,426 1,071,732 (4,133) 已付所得税 - - - 经营活动产生的现金流量净额 451,426 1,071,732 (4,133)